1. |
Robert-Boire V, Rosca L, Samson Y, et al. Clinical presentation and outcome of patients with optic pathway glioma[J]. Pediatr Neurol, 2017, 75: 55-60. DOI: 10.1016/j.pediatrneurol.2017.06.019.
|
2. |
Segal L, Darvish-Zargar M, Dilenge ME, et al. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients[J]. J JAAPOS, 2010, 14(2): 155-158. DOI: 10.1016/j.jaapos.2009.11.020.
|
3. |
Avery RA, Bouffet E, Packer RJ, et al. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas[J]. Invest Ophthalmol Vis Sci, 2013, 54(2): 1034-1038. DOI: 10.1167/iovs.12-11385.
|
4. |
Avery RA, Fisher MJ, Liu GT. Optic pathway gliomas[J]. J Neuroophthalmol, 2011, 31(3): 269-278. DOI: 10.1097/WNO.0b013e31822aef82.
|
5. |
Purohit BS, Vargas MI, Ailianou A, et al. Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging[J]. Insights Imaging, 2016, 7(1): 43-68. DOI: 10.1007/s13244-015-0443-8.
|
6. |
Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1[J]. J Child Neurol, 2018, 33(1): 73-81. DOI: 10.1177/0883073817739509.
|
7. |
Marsault P, Ducassou S, Menut F, et al. Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children[J]. Neuroradiology, 2019, 61(6): 711-720. DOI: 10.1007/s00234-019-02198-w.
|
8. |
Binning MJ, Liu JK, Kestle JR, et al. Optic pathway gliomas: a review[J]. Neurosurg Focus, 2007, 23(5): E2. DOI: 10.3171/FOC-07/11/E2.
|
9. |
Shapey J, Danesh-Meyer HV, Kaye AH, et al. Diagnosis and management of optic nerve glioma[J]. J Clin Neurosci, 2011, 18(12): 1585-1591. DOI: 10.1016/j.jocn.2011.09.003.
|
10. |
Narain S, Kini A, Ramasubramanian A. Advancements in the management of optic pathway gliomas[J/OL]. Ocular Oncology, 2019, 2019: 47-60[2019-07-11]. DOI: 10.1007/978-981-13-7538-5_4. https://link.springer.com/chapter/10.1007%2F978-981-13-7538-5_4. /. DOI:10.1007/978-981-13-7538-5_4..
|
11. |
Farazdaghi MK, Katowitz WR, Avery RA. Current treatment of optic nerve gliomas[J]. Curr Opin Ophthalmol, 2019, 30(5): 356-363. DOI: 10.1097/ICU.0000000000000587.
|
12. |
Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood[J]. Curr Opin Ophthalmol, 2017, 28(3): 289-295. DOI: 10.1097/ICU.0000000000000370.
|
13. |
Minturn JE, Fisher MJ. Gliomas in children[J]. Curr Treat Options Neurol, 2013, 15(3): 316-327. DOI: 10.1007/s11940-013-0225-x.
|
14. |
Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma[J]. Neuro Oncol, 2007, 9(2): 161-168. DOI: 10.1215/15228517-2006-030.
|
15. |
Azizi AA, Schouten-van Meeteren AYN. Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey[J]. J Neurooncol, 2018, 136(1): 127-134. DOI: 10.1007/s11060-017-2630-6.
|
16. |
Combs SE, Schulz-Ertner D, Moschos D, et al. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome[J]. Int J Radiat Oncol Biol Phys, 2005, 62(3): 814-819. DOI: 10.1016/j.ijrobp.2004.12.081.
|
17. |
Tsang DS, Murphy ES, Merchant TE. Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3): 642-651. DOI: 10.1016/j.ijrobp.2017.07.023.
|
18. |
Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era[J]. Neuro Oncol, 2017, 19(6): 750-761. DOI: 10.1093/neuonc/now209.
|
19. |
Cheng Y, Tian H. Current development status of MEK inhibitors[J]. Molecules, 2017, 22(10): 1551. DOI: 10.3390/molecules22101551.
|
20. |
Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase Ⅰ trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study[J]. Neuro Oncol, 2017, 19(8): 1135-1144. DOI: 10.1093/neuonc/now282.
|
21. |
Avery RA, Trimboli-Heidler C, Kilburn LB. Separation of outer retinal layers secondary to selumetinib[J]. J AAPOS, 2016, 20(3): 268-271. DOI: 10.1016/j.jaapos.2016.01.012.
|
22. |
Bartels U, Hawkins C, Jing M, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas[J]. J Neurosurg, 2006, 104(5): 314-320. DOI: 10.3171/ped.2006.104.5.314.
|
23. |
武万水, 刘晶晶, 孙艳玲, 等. 贝伐珠单抗治疗儿童视路胶质瘤的疗效分析[J]. 中国当代儿科杂志, 2019, 21(12): 1193-1197. DOI: 10.7499/j.issn.1008-8830.2019.12.008.Wu WS, Liu JJ, Sun YL, et al. Effect of bevacizumab in treatment of children with optic pathway glioma[J]. Chinese Journal of Contemporary Pediatrics, 2019, 21(12): 1193-1197. DOI: 10.7499/j.issn.1008-8830.2019.12.008.
|
24. |
Lu VM, Welby JP, Nesvick CL, et al. Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates[J]. Neurooncol Pract, 2020, 7(4): 359-368. DOI: 10.1093/nop/npz076.
|
25. |
Nair AG, Pathak RS, Iyer VR, et al. Optic nerve glioma: an update[J]. Int Ophthalmol, 2014, 34(4): 999-1005. DOI: 10.1007/s10792-014-9942-8.
|
26. |
Dong Q, Yang B, Han JG, et al. A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways[J]. Cancer Lett, 2019, 455: 60-72. DOI: 10.1016/j.canlet.2019.04.031.
|